In vivo administration of a commercial source of Cucurbitacin-I (JSI-124) into male athymic nu/nu mice injected subcutaneously with ST88-14 cells led to a significant reduction in NF1-deficient tumor growth compared to controls and supports STAT3 inhibition as a promising therapeutic strategy for NF1-associated tumors. This evidence concerns the gene NF1 and neoplasm.